article thumbnail

Biological Characterization of One Oxadiazole Derivative (5(4‐Hydroxyphenyl)‐2‐(N‐Phenyl Amino)‐1,3,4‐Oxadiazole): In Vitro, In Silico, and Network Pharmacological Approaches

Chemical Biology and Drug Design

5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. These results were confirmed by molecular modeling and bioinformatics tools. In the anticancer test, the compound showed strong anticancer activity in pancreatic cancer with apoptotic signaling pathways.

article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature. He was an early employee of Recursion Pharmaceuticals, where he scaled their high-content imaging platform by multiple orders of magnitude before joining Enveda in 2021. References Newman DJ, Cragg GM.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. Their work was recently published in Bioinformatics. We chat with him about otargen, and the importance of sharing open-source resources within the bioinformatics community.

article thumbnail

Finding the right CDMO partner for cell line development

Drug Target Review

Finally, comprehensive genetic knowledge also facilitates the use of powerful bioinformatic tools that strengthen the cell-line development process, especially for enhanced protein expression or monoclonality assessment.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.

article thumbnail

Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases

The Pharma Data

” Arthur Oubrie, Chief Scientific Officer of Lead Pharma, added: “This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform. . Lead Pharma may receive payments of up to €260 million plus royalties on sales. OSS, Netherlands , Nov.

article thumbnail

Three reflections from David Hulcoop's first year as Executive Director

The Open Targets Blog

The Open Targets consortium is working at its largest scale to date, bringing together two scientific institutes and five pharmaceutical partners. Building and Sustaining I have huge admiration for the incredible teams at EMBL’s European Bioinformatics Institute and beyond who build and sustain knowledge resources for the community.